Analysts’ Viewpoint
Rise in prevalence of inflammatory diseases is driving the global anti-inflammatory therapeutics market. Anti-inflammatory therapies in use today primarily consist of steroidal and non-steroidal drugs. Controlling inflammatory response is critical for preventing irreversible tissue damage and controlling symptoms. Increase in number of pipeline products used in anti-inflammatory therapeutics is propelling market expansion. Furthermore, introduction of innovative biologic agents and small molecule drugs is expected to bolster the global inflammatory diseases market size during the forecast period.
Research & development on novel medications and technological advancements in drug delivery systems for treatment of inflammatory diseases offer lucrative opportunities to market players. Companies are focusing introducing more effective and low cost NSAIDs and corticosteroids in order to increase market share and presence.
Medications categorized as anti-inflammatory therapeutics are specifically formulated to diminish inflammation within the body. These function by targeting the fundamental processes of inflammation, either by obstructing the generation or activity of inflammatory substances or by adjusting the immune response.
Non-steroidal anti-inflammatory drugs (NSAIDs) represent a widely utilized category of drugs that mitigate inflammation, alleviate pain, and reduce fever. Their mechanism involves impeding the action of the enzyme cyclooxygenase (COX), which is responsible for generating inflammatory agents known as prostaglandins.
Anti-inflammatory therapeutics, such as NSAIDs, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs), are quite effective in the management of various conditions, including rheumatoid arthritis.
These medications aid in alleviating the symptoms and impeding the progression of the disease. Introduction of innovative biologic agents and small molecule drugs is likely to drive the global anti-inflammatory therapeutics market growth during the forecast period.
Chronic inflammation in various body parts, which can result in tissue damage and other health issues, is a hallmark of inflammatory diseases. These include conditions such as rheumatoid arthritis, inflammatory bowel disease, asthma, multiple sclerosis, and psoriasis.
Several factors contribute to the rising prevalence of inflammatory diseases. These include aging population, sedentary lifestyles, unhealthy dietary habits, environmental factors, and genetic predisposition.
Improvement in diagnostic techniques and increase in awareness among individuals and healthcare professionals have led to better identification and diagnosis of these conditions.
Rise in prevalence of inflammatory diseases has increased demand for effective treatment options. This has driven research and development efforts in the field of anti-inflammatory therapeutics, leading to the introduction of new drugs and therapies.
Pharmaceutical companies are investing in the development of novel anti-inflammatory drugs with improved efficacy, safety profiles, and modes of administration.
Hence, rise in prevalence of inflammatory diseases is anticipated to propel the global anti-inflammatory industry growth in the next few years.
Biologics, such as monoclonal antibodies and cytokine inhibitors, have shown promising results in managing various inflammatory diseases. These drugs target specific molecules and pathways involved in inflammation, providing more targeted and effective treatment options.
Several pipeline products are being developed for anti-inflammatory therapeutics. The field of anti-inflammatory therapeutics is witnessing a surge in the development of pipeline products.
Ongoing research and development efforts aim to introduce innovative treatments with improved efficacy and safety profiles for various inflammatory diseases. Thus, growing adoption of biologic drugs is fueling the global anti-inflammatory therapeutics market development.
In terms of drug class, the anti-inflammatory biologics segment accounted for the largest global anti-inflammatory therapeutics market share in 2022. Biologics are a type of therapeutic derived from living organisms that target specific molecules involved in the inflammatory process. These have transformed the treatment of diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Biologics work by inhibiting specific immune system components that contribute to inflammation. They are usually given as injections or infusions and have targeted and potent anti-inflammatory effects. Biologics have shown superior efficacy in managing chronic inflammatory conditions with fewer side effects when compared to traditional NSAIDs or corticosteroids.
Anti-inflammatory biologics have grown in popularity and use over the years, owing to factors such as rise in prevalence of inflammatory diseases, improved understanding of disease mechanisms, and development of novel biologic therapies.
Based on application, the auto-immune diseases segment dominated the global anti-inflammatory therapeutics market demand in 2022. Anti-inflammatory therapeutics are frequently used in the treatment of autoimmune diseases to manage and control the inflammatory response.
Anti-inflammatory drugs such as NSAIDs, corticosteroids, and biologic therapies are commonly used in order to suppress inflammation and alleviate symptoms.
Several targeted therapies and biologics specifically designed for autoimmune disorders have been developed and introduced in the market, offering improved efficacy and safety profiles when compared to traditional treatments.
In terms of route of administration, the injection segment held significant share of the global anti-inflammatory therapeutics market in 2022. Several anti-inflammatory biologics, such as monoclonal antibodies, are administered via injections or infusions.
This route of administration allows for direct delivery of the medication into the bloodstream, ensuring rapid and systemic distribution throughout the body. Injections are often preferred for their convenience, precise dosing, and the ability to maintain therapeutic drug levels over an extended period.
Based on distribution channel, the hospital pharmacies segment dominated the global market in 2022. Hospital pharmacies are critical in the distribution and dispensing of anti-inflammatory medications. They serve as a central hub for medication management within hospitals and healthcare facilities.
Hospital pharmacies are in charge of acquiring, storing, and dispensing medications to patients, including anti-inflammatory drugs. They ensure that these therapeutics are available and provide specialized services, such as compounding and sterile preparations, to meet the specific needs of patients receiving anti-inflammatory treatments.
As per anti-inflammatory therapeutics market forecast, North America dominated the global industry in 2022. The region has a well-developed healthcare infrastructure, advanced research facilities, and large patient population, which collectively contribute to market progress in the region.
Several factors have propelled the demand for anti-inflammatory therapeutics in North America. These include rise in prevalence of chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and asthma. Additionally, lifestyle factors such as sedentary lifestyle, unhealthy dietary habit, and increase in geriatric population contributed to high the incidence of inflammatory conditions in the region.
Around 1.3 million adults in the U.S. suffered from rheumatoid arthritis (RA) in 2021, accounting for 0.6% to 1% of the adult population. The prevalence of work disability associated with rheumatoid arthritis was around 35% among those with rheumatoid arthritis. Furthermore, the total annual health cost for rheumatoid arthritis patient population in the U.S. has been estimated at US$ 19.3 Bn.
High healthcare expenditure, robust reimbursement frameworks, and favorable reimbursement scenario in countries such as the U.S. and Canada are bolstering market growth in North America. Availability of advanced diagnostic tools and technologies for early diagnosis and monitoring of inflammatory conditions also contributes to high demand for anti-inflammatory therapeutics.
Leading players in the global anti-inflammatory therapeutics market have adopted strategies such as product portfolio expansion and merger & acquisition in order to increase market share.
AbbVie, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Pfizer, Inc., Novartis AG, GlaxoSmithKline plc, Amgen, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, and Sanofi are the prominent players in the market.
The anti-inflammatory therapeutics market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent Anti-inflammatory therapeutics market developments.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 94.6 Bn |
| Forecast (Value) in 2031 | US$ 149.5 Bn |
| Growth Rate (CAGR) | 5.1% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It provides segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 94.6 Bn in 2022
It is projected to reach more than US$ 149.5 Mn by 2031
It is anticipated to grow at a CAGR of 5.1% from 2023 to 2031
Rise in prevalence of inflammatory diseases and ongoing research & development activities
North America is projected to account for major market share during the forecast period
AbbVie, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Pfizer, Inc., Novartis AG, GlaxoSmithKline plc., Amgen, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, and Sanofi.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anti-inflammatory Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. List of Biologicals Used to Treat Chronic Autoimmune and Inflammatory Diseases
5.3. Disease Prevalence & Incidence Rate Globally With Key Countries
5.4. COVID-19 Pandemic Impact on Industry
6. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Anti-inflammatory Biologics
6.3.2. NSAIDs
6.3.3. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Auto-immune Diseases
7.3.1.1. Rheumatoid Arthritis
7.3.1.2. Psoriasis
7.3.1.3. Multiple Sclerosis
7.3.1.4. Crohn's Disease
7.3.1.5. Ulcerative Colitis
7.3.1.6. Others
7.3.2. Respiratory Conditions
7.3.2.1. COPD
7.3.2.2. Asthma
7.4. Market Attractiveness Analysis, by Application
8. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Oral
8.3.2. Injection
8.3.3. Topical
8.3.4. Inhalation
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Anti-inflammatory Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. Anti-inflammatory Biologics
11.2.2. NSAIDs
11.2.3. Others
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Auto-immune Diseases
11.3.1.1. Rheumatoid Arthritis
11.3.1.2. Psoriasis
11.3.1.3. Multiple Sclerosis
11.3.1.4. Crohn's Disease
11.3.1.5. Ulcerative Colitis
11.3.1.6. Others
11.3.2. Respiratory Conditions
11.3.2.1. COPD
11.3.2.2. Asthma
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Injection
11.4.3. Topical
11.4.4. Inhalation
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Application
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country/Sub-region
12. Europe Anti-inflammatory Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Anti-inflammatory Biologics
12.2.2. NSAIDs
12.2.3. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Auto-immune Diseases
12.3.1.1. Rheumatoid Arthritis
12.3.1.2. Psoriasis
12.3.1.3. Multiple Sclerosis
12.3.1.4. Crohn's Disease
12.3.1.5. Ulcerative Colitis
12.3.1.6. Others
12.3.2. Respiratory Conditions
12.3.2.1. COPD
12.3.2.2. Asthma
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Injection
12.4.3. Topical
12.4.4. Inhalation
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Application
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Anti-inflammatory Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Anti-inflammatory Biologics
13.2.2. NSAIDs
13.2.3. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Auto-immune Diseases
13.3.1.1. Rheumatoid Arthritis
13.3.1.2. Psoriasis
13.3.1.3. Multiple Sclerosis
13.3.1.4. Crohn's Disease
13.3.1.5. Ulcerative Colitis
13.3.1.6. Others
13.3.2. Respiratory Conditions
13.3.2.1. COPD
13.3.2.2. Asthma
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Injection
13.4.3. Topical
13.4.4. Inhalation
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Application
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Anti-inflammatory Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2031
14.2.1. Anti-inflammatory Biologics
14.2.2. NSAIDs
14.2.3. Others
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Auto-immune Diseases
14.3.1.1. Rheumatoid Arthritis
14.3.1.2. Psoriasis
14.3.1.3. Multiple Sclerosis
14.3.1.4. Crohn's Disease
14.3.1.5. Ulcerative Colitis
14.3.1.6. Others
14.3.2. Respiratory Conditions
14.3.2.1. COPD
14.3.2.2. Asthma
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Injection
14.4.3. Topical
14.4.4. Inhalation
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Application
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Anti-inflammatory Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2017–2031
15.2.1. Anti-inflammatory Biologics
15.2.2. NSAIDs
15.2.3. Others
15.3. Market Value Forecast, by Application, 2017–2031
15.3.1. Auto-immune Diseases
15.3.1.1. Rheumatoid Arthritis
15.3.1.2. Psoriasis
15.3.1.3. Multiple Sclerosis
15.3.1.4. Crohn's Disease
15.3.1.5. Ulcerative Colitis
15.3.1.6. Others
15.3.2. Respiratory Conditions
15.3.2.1. COPD
15.3.2.2. Asthma
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Oral
15.4.2. Injection
15.4.3. Topical
15.4.4. Inhalation
15.5. Market Value Forecast, by Distribution Channel, 2017–2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Class
15.7.2. By Application
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. AbbVie, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Merck & Co., Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Johnson & Johnson Services, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Pfizer, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Novartis AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. GlaxoSmithKline plc
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Amgen, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. F. Hoffmann-La Roche Ltd.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. AstraZeneca
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Sanofi
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
List of Tables
Table 01: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 03: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 04: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 05: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 08: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 09: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 10: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 13: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 14: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 15: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 18: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 19: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 20: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 23: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 24: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 25: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 28: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 29: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 30: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Anti-inflammatory Therapeutics Market Value Share, by Drug Class, 2022
Figure 03: Global Anti-inflammatory Therapeutics Market Value Share, by Application, 2022
Figure 04: Global Anti-inflammatory Therapeutics Market Value Share, by Route of Administration, 2022
Figure 05: Global Anti-inflammatory Therapeutics Market Value Share, by Distribution Channel, 2022
Figure 06: Global Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 07: Global Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 08: Global Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 09: Global Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application 2023–2031
Figure 10: Global Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 11: Global Anti-inflammatory Therapeutics Market Attractiveness Analysis, Route of Administration, 2023–2031
Figure 12: Global Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 13: Global Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 14: Global Anti-inflammatory Therapeutics Market Value Share Analysis, by Region, 2022 and 2031
Figure 15: Global Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Region, 2023–2031
Figure 16: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 17: North America Anti-inflammatory Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 18: North America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Country, 2023–2031
Figure 19: North America Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 20: North America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 21: North America Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 22: North America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application 2023–2031
Figure 23: North America Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 24: North America Anti-inflammatory Therapeutics Market Attractiveness Analysis, Route of Administration, 2023–2031
Figure 25: North America Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 26: North America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 28: Europe Anti-inflammatory Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 29: Europe Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 30: Europe Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 31: Europe Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 32: Europe Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 33: Europe Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application 2023–2031
Figure 34: Europe Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 35: Europe Anti-inflammatory Therapeutics Market Attractiveness Analysis, Route of Administration, 2023–2031
Figure 36: Europe Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 37: Europe Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 38: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 39: Asia Pacific Anti-inflammatory Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 40: Asia Pacific Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 41: Asia Pacific Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 42: Asia Pacific Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 43: Asia Pacific Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 44: Asia Pacific Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application 2023–2031
Figure 45: Asia Pacific Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 46: Asia Pacific Anti-inflammatory Therapeutics Market Attractiveness Analysis, Route of Administration, 2023–2031
Figure 47: Asia Pacific Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 48: Asia Pacific Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 49: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 50: Latin America Anti-inflammatory Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 51: Latin America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 52: Latin America Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 53: Latin America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 54: Latin America Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 55: Latin America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 56: Latin America Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 57: Latin America Anti-inflammatory Therapeutics Market Attractiveness Analysis, Route of Administration, 2023–2031
Figure 58: Latin America Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 59: Latin America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 60: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 61: Middle East & Africa Anti-inflammatory Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 62: Middle East & Africa Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 63: Middle East & Africa Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 64: Middle East & Africa Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 65: Middle East & Africa Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 66: Middle East & Africa Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application 2023–2031
Figure 67: Middle East & Africa Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 68: Middle East & Africa Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 69: Middle East & Africa Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 70: Middle East & Africa Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 71: Global Anti-inflammatory Therapeutics Market Share Analysis, by Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Anti-inflammatory Therapeutics Market
*86 figures and 60 tables includes